Acumen Pharmaceuticals Reports Third-Quarter 2026 Net Loss of $25.4 Million
Acumen reported a diluted loss per share of $0.35, narrowed from $0.44 a year earlier. Its net loss was $25.4 million, compared with $26.5 million in the year-ago quarter.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.